

<b>APPLICANT</b> (stamp or sticker acceptable)	<b>PATIENT NHI:</b> .....	<b>REFERRER</b> Reg No: .....
Reg No: .....	First Names: .....	First Names: .....
Name: .....	Surname: .....	Surname: .....
Address: .....	DOB: .....	Address: .....
.....	.....	.....
Fax Number: .....	Fax Number: .....	

### Long-acting Somatostatin Analogues

#### Initial application — Malignant Bowel Obstruction

Applications from any relevant practitioner. Approvals valid for 2 months.

**Prerequisites**(tick boxes where appropriate)

<input type="checkbox"/>	The patient has nausea* and vomiting* due to malignant bowel obstruction*
<b>and</b>	
<input type="checkbox"/>	Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has not been successful
<b>and</b>	
<input type="checkbox"/>	Treatment to be given for up to 4 weeks

Note: Indications marked with \* are unapproved indications.

#### Renewal — Malignant Bowel Obstruction

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 3 months.

**Prerequisites**(tick box where appropriate)

<input type="checkbox"/>	The treatment remains appropriate and the patient is benefiting from treatment
--------------------------	--

#### Initial application — Acromegaly

Applications from any relevant practitioner. Approvals valid for 3 months.

**Prerequisites**(tick boxes where appropriate)

<input type="checkbox"/>	The patient has acromegaly
<b>and</b>	
<input type="checkbox"/>	Treatment with surgery and radiotherapy is not suitable or was unsuccessful
<b>or</b>	
<input type="checkbox"/>	Treatment is for an interim period while awaiting the beneficial effects of radiotherapy
<b>and</b>	
<input type="checkbox"/>	Treatment with a dopamine agonist has been unsuccessful

#### Renewal — Acromegaly

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 2 years.

**Prerequisites**(tick box where appropriate)

<input type="checkbox"/>	IGF1 levels have decreased since starting treatment
--------------------------	---

Note: In patients with acromegaly, treatment should be discontinued if IGF1 levels have not decreased 3 months after treatment. In patients treated with radiotherapy treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following treatment withdrawal for at least 4 weeks

**I confirm the above details are correct and that in signing this form I understand I may be audited.**

Signed: ..... Date: .....

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: [customerservice@health.govt.nz](mailto:customerservice@health.govt.nz)

<b>APPLICANT</b> (stamp or sticker acceptable)	<b>PATIENT NHI:</b> .....	<b>REFERRER</b> Reg No: .....
Reg No: .....	First Names: .....	First Names: .....
Name: .....	Surname: .....	Surname: .....
Address: .....	DOB: .....	Address: .....
.....	.....	.....
Fax Number: .....	.....	Fax Number: .....

**Long-acting Somatostatin Analogues** - *continued*

**Initial application — pre-operative acromegaly**

Applications from any relevant practitioner. Approvals valid for 12 months.

**Prerequisites**(tick boxes where appropriate)

<input type="checkbox"/> Patient has acromegaly
<b>and</b>
<input type="checkbox"/> Patient has a large pituitary tumour, greater than 10 mm at its widest
<b>and</b>
<input type="checkbox"/> Patient is scheduled to undergo pituitary surgery in the next six months

**Initial application — Other Indications**

Applications from any relevant practitioner. Approvals valid for 2 years.

**Prerequisites**(tick boxes where appropriate)

<input type="checkbox"/> VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery						
<b>or</b>						
<table border="0"><tr><td><input type="checkbox"/> Gastrinoma</td></tr><tr><td><b>and</b></td></tr><tr><td><table border="0"><tr><td><input type="checkbox"/> Surgery has been unsuccessful</td></tr><tr><td><b>or</b></td></tr><tr><td><input type="checkbox"/> Patient has metastatic disease after treatment with H2 antagonist or proton pump inhibitors has been unsuccessful</td></tr></table></td></tr></table>	<input type="checkbox"/> Gastrinoma	<b>and</b>	<table border="0"><tr><td><input type="checkbox"/> Surgery has been unsuccessful</td></tr><tr><td><b>or</b></td></tr><tr><td><input type="checkbox"/> Patient has metastatic disease after treatment with H2 antagonist or proton pump inhibitors has been unsuccessful</td></tr></table>	<input type="checkbox"/> Surgery has been unsuccessful	<b>or</b>	<input type="checkbox"/> Patient has metastatic disease after treatment with H2 antagonist or proton pump inhibitors has been unsuccessful
<input type="checkbox"/> Gastrinoma						
<b>and</b>						
<table border="0"><tr><td><input type="checkbox"/> Surgery has been unsuccessful</td></tr><tr><td><b>or</b></td></tr><tr><td><input type="checkbox"/> Patient has metastatic disease after treatment with H2 antagonist or proton pump inhibitors has been unsuccessful</td></tr></table>	<input type="checkbox"/> Surgery has been unsuccessful	<b>or</b>	<input type="checkbox"/> Patient has metastatic disease after treatment with H2 antagonist or proton pump inhibitors has been unsuccessful			
<input type="checkbox"/> Surgery has been unsuccessful						
<b>or</b>						
<input type="checkbox"/> Patient has metastatic disease after treatment with H2 antagonist or proton pump inhibitors has been unsuccessful						
<b>or</b>						
<table border="0"><tr><td><input type="checkbox"/> Insulinomas</td></tr><tr><td><b>and</b></td></tr><tr><td><input type="checkbox"/> Surgery is contraindicated or has not been successful</td></tr></table>	<input type="checkbox"/> Insulinomas	<b>and</b>	<input type="checkbox"/> Surgery is contraindicated or has not been successful			
<input type="checkbox"/> Insulinomas						
<b>and</b>						
<input type="checkbox"/> Surgery is contraindicated or has not been successful						
<b>or</b>						
<table border="0"><tr><td><input type="checkbox"/> For pre-operative control of hypoglycaemia and for maintenance therapy</td></tr></table>	<input type="checkbox"/> For pre-operative control of hypoglycaemia and for maintenance therapy					
<input type="checkbox"/> For pre-operative control of hypoglycaemia and for maintenance therapy						
<b>or</b>						
<table border="0"><tr><td><input type="checkbox"/> Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis)</td></tr><tr><td><b>and</b></td></tr><tr><td><input type="checkbox"/> Disabling symptoms not controlled by maximal medical therapy</td></tr></table>	<input type="checkbox"/> Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis)	<b>and</b>	<input type="checkbox"/> Disabling symptoms not controlled by maximal medical therapy			
<input type="checkbox"/> Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis)						
<b>and</b>						
<input type="checkbox"/> Disabling symptoms not controlled by maximal medical therapy						

Note: The use of a long-acting somatostatin analogue in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will not be funded under Special Authority

**Renewal — Other Indications**

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 2 years.

**Prerequisites**(tick box where appropriate)

<input type="checkbox"/> The treatment remains appropriate and the patient is benefiting from treatment
---

**I confirm the above details are correct and that in signing this form I understand I may be audited.**

Signed: ..... Date: .....

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: [customerservice@health.govt.nz](mailto:customerservice@health.govt.nz)